New Metabolic Approaches to Cancer Cell Research

Biolog invites you to a webinar on Phenotype MicroArray™ Technology presented by
Dr. Barry Bochner, CEO & CSO.  This Technology can enable discoveries by analyzing
biochemical pathway activities of cancer cells in new ways.

The webinar will explain the fundamental technology and then illustrate the uses and benefits:

  • Study the Warburg Effect in a new way
  • Analyze metabolic reprogramming in cancer cell lines
  • Develop novel anti-cancer screens for chemical libraries
  • Measure effectiveness of anti-cancer drugs singly and in combinations
  • Learn about advantages over mass spec and NMR approaches

Register for the Webinar!
January 19, 2017 @ 1:00pm EST, 10 am PST

About the Speaker

Barry Bochner, Ph.D.

CEO/CSO

bbochner@biolog.com

Your invited to a brief overview on Phenotype MicroArray (PM) technology from dye reporter chemistry to basic workflow and data analysis:

- How the Phenotype MicroArray technology works

- How it can increase phenotyping productivity in your laboratory

- Facilitate your research

 

We will also discuss common scientific applications including:

- Metabolic phenotypes

- Strain discrimination

- Functional phenomics

- Chemical phenomics

- Metabolic model validation

Barry Bochner is the CEO and CSO and co-founder of Biolog, Inc. He has broad interests in biology ranging from microbial to human cells, with particular emphasis in cell metabolism and physiology. Dr. Bochner has S.B, S. M. degrees in Biology from MIT, a Ph.D. in Bioengineering from University of Michigan, and did postdoctoral work in Biochemistry at University of California, Berkeley.